Aclaris Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

ATI-50001 / Aclaris, Rigel

NCT05828459: First-in-human Study of OT-A201 in Patients with Selected Hematological Malignancies and Solid Tumors

Recruiting

150

Europe

OT-A201, IMids, lenalidomide, pomalidomide, Bevacizumab, Paclitaxel, TBD Compound

Onward Therapeutics

Hematological Malignancy, Solid Tumor

01/27

07/27

zunsemetinib (ATI-450) / Aclaris

NCT05216224: ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed

ATI-450, Zunsemetinib, Placebo oral tablet, Placebo

Aclaris Therapeutics, Inc.

Hidradenitis Suppurativa

12/22

01/23

NCT05279417 / 2021-002860-31: ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Completed

251

Europe, US, RoW

ATI-450 50 mg oral tablet BID, zunsemetinib, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID

Aclaris Therapeutics, Inc., Aclaris Therapeutics, Inc.

Rheumatoid Arthritis

09/23

10/23

2021-002860-31: ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone ATI-450 plus methotrexát (MTX) versus placebo plus MTX u pacientů se středně těžkou až těžkou aktivní revmatoidní artritidou (RA), kteří měli nedostatečnou odpověď na MTX samotný

Not yet recruiting

240

RoW

Zunsemetinib, ATI-450, Tablet

Aclaris Therapeutics, Inc., Aclaris Therapeutics, Inc.

Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone, Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone, Diseases [C] - Musculoskeletal Diseases [C05]

NCT05511519 / 2022-000847-62: Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Terminated

Europe, US

ATI-450, CDD-450, Placebo Oral Tablet

Aclaris Therapeutics, Inc.

Psoriatic Arthritis

12/23

01/24

NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting

1/2

152

Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab

Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

05/32

NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting

1/2

150

ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents

Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense

Breast Cancer, Cancer of Breast

05/25

04/28

NCT06648434: MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting

Zunsemetinib, ATI-450, mFOLFIRINOX

Washington University School of Medicine, National Cancer Institute (NCI), Aclaris Therapeutics, Inc.

Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas

04/27

03/30

ATI-2138 / Aclaris

NCT06585202: Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis

Active, not recruiting

ATI-2138

Aclaris Therapeutics, Inc.

Atopic Dermatitis

04/25

05/25

ATI-1777 / Aclaris

NCT05432596: Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Completed

250

ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle

Aclaris Therapeutics, Inc.

Atopic Dermatitis

10/23

11/23

bosakitug (BSI-045B) / Aclaris

TQC2731-III-01, NCT06829784: TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

Recruiting

660

RoW

TQC2731 injection, Placebo

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Asthma

06/27

NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Recruiting

RoW

210mg of TQC2731 injection, 420mg of TQC2731 injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Chronic Rhinosinusitis With Nasal Polyps

05/25

02/26

NCT05472324: Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

Recruiting

220

RoW

TQC2731 injection, Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Severe Asthma

10/24

ADAMANT, NCT05932654: POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Completed

BSI-045B

Biosion, Inc.

Atopic Dermatitis

09/24

TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting

258

RoW

TQC2731 injection, TQC2731 Placebo

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Chronic Obstructive Pulmonary Disease

12/26

09/27

NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

Recruiting

RoW

TQC2731 injection, TQC2731 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chronic Sinusitis, Nasal Polyps

07/25

09/25

NCT05114889: Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

Completed

RoW

BSI-045B

Biosion, Inc., Southern Star Research Pty Ltd.

Atopic Dermatitis

02/23

NCT04923607: Phase I Clinical Trial of TQC2731 Injection

Not yet recruiting

RoW

TQC2731, Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Asthma Severe Persistent Controlled

08/23

ATI-2231 / Aclaris

NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn

ATI-2231

Washington University School of Medicine, Aclaris Therapeutics, Inc.

Advanced Solid Tumor, Advanced Solid Tumor Malignancies

06/25

CDD-2676 / Aclaris

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

ATI-50001 / Aclaris, Rigel

NCT05828459: First-in-human Study of OT-A201 in Patients with Selected Hematological Malignancies and Solid Tumors

Recruiting

150

Europe

OT-A201, IMids, lenalidomide, pomalidomide, Bevacizumab, Paclitaxel, TBD Compound

Onward Therapeutics

Hematological Malignancy, Solid Tumor

01/27

07/27

zunsemetinib (ATI-450) / Aclaris

NCT05216224: ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed

ATI-450, Zunsemetinib, Placebo oral tablet, Placebo

Aclaris Therapeutics, Inc.

Hidradenitis Suppurativa

12/22

01/23

NCT05279417 / 2021-002860-31: ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Completed

251

Europe, US, RoW

ATI-450 50 mg oral tablet BID, zunsemetinib, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID

Aclaris Therapeutics, Inc., Aclaris Therapeutics, Inc.

Rheumatoid Arthritis

09/23

10/23

Not yet recruiting

240

RoW

Zunsemetinib, ATI-450, Tablet

Aclaris Therapeutics, Inc., Aclaris Therapeutics, Inc.

NCT05511519 / 2022-000847-62: Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Terminated

Europe, US

ATI-450, CDD-450, Placebo Oral Tablet

Aclaris Therapeutics, Inc.

Psoriatic Arthritis

12/23

01/24

NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting

1/2

152

Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab

Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

05/32

NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting

1/2

150

ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents

Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense

Breast Cancer, Cancer of Breast

05/25

04/28

NCT06648434: MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting

Zunsemetinib, ATI-450, mFOLFIRINOX

Washington University School of Medicine, National Cancer Institute (NCI), Aclaris Therapeutics, Inc.

Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas

04/27

03/30

ATI-2138 / Aclaris

NCT06585202: Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis

Active, not recruiting

ATI-2138

Aclaris Therapeutics, Inc.

Atopic Dermatitis

04/25

05/25

ATI-1777 / Aclaris

NCT05432596: Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Completed

250

ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle

Aclaris Therapeutics, Inc.

Atopic Dermatitis

10/23

11/23

bosakitug (BSI-045B) / Aclaris

TQC2731-III-01, NCT06829784: TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

Recruiting

660

RoW

TQC2731 injection, Placebo

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Asthma

06/27

NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Recruiting

RoW

210mg of TQC2731 injection, 420mg of TQC2731 injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Chronic Rhinosinusitis With Nasal Polyps

05/25

02/26

NCT05472324: Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

Recruiting

220

RoW

TQC2731 injection, Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Severe Asthma

10/24

ADAMANT, NCT05932654: POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Completed

BSI-045B

Biosion, Inc.

Atopic Dermatitis

09/24

TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting

258

RoW

TQC2731 injection, TQC2731 Placebo

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Chronic Obstructive Pulmonary Disease

12/26

09/27

NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

Recruiting

RoW

TQC2731 injection, TQC2731 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chronic Sinusitis, Nasal Polyps

07/25

09/25

NCT05114889: Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

Completed

RoW

BSI-045B

Biosion, Inc., Southern Star Research Pty Ltd.

Atopic Dermatitis

02/23

NCT04923607: Phase I Clinical Trial of TQC2731 Injection

Not yet recruiting

RoW

TQC2731, Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Asthma Severe Persistent Controlled

08/23

ATI-2231 / Aclaris

NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn

ATI-2231

Washington University School of Medicine, Aclaris Therapeutics, Inc.

Advanced Solid Tumor, Advanced Solid Tumor Malignancies

06/25

CDD-2676 / Aclaris

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites